Integrating multiomics data into the drug development process is transforming the future of drug commercialization and manufacturing. In this webinar, ZS’s Bruce Press sits down with Seqera CEO and Co-founder Evan Floden to discuss the crucial role of regulatory-grade bioinformatics in advancing personalized medicine and accelerating the development of precision therapies. They explore how ZS and Seqera’s strategic partnership enhances compliance and efficiency by integrating traceable, auditable workflows into clinical development and manufacturing.
Watch to learn:
- About the role of regulatory-grade bioinformatics in ensuring compliance and precision throughout the pharmaceutical life cycle
- How GxP-compliant bioinformatics workflows are critical for the analysis of multiomics data in clinical development and manufacturing
- Strategies for validating and maintaining regulatory-grade systems to meet stringent safety, efficacy and regulatory standards in drug commercialization
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
